GSK CEO’s share interests rise by 1,413 on dividends

The reported transactions span ordinary shares and ADS, with Julie Brown’s Performance Share Plan shares subject to a 2-year holding period.

Rhea-AI Filing Summary

GSK plc reported dividend reinvestment-related increases in executives’ notional interests on October 12, 2026, following dividends paid to shareholders on October 8, 2026. Under the Deferred Annual Bonus Plan, Chief Executive Officer Luke Miels had an increase of 1,413 ordinary shares; Chief Financial Officer Julie Brown, 1,863; SVP and Group General Counsel, Legal and Compliance James Ford, 783; President, Corporate Development David Redfern, 894; President, Global Supply Chain Regis Simard, 1,103; President, Global Affairs Philip Thomson, 660; CEO, ViiV Healthcare and President, Global Health, GSK Deborah Waterhouse, 987; and Chief Scientific Officer Tony Wood, 1,157. Each was priced at £17.3550. Chief Digital and Technology Officer Shobie Ramakrishnan had a notional-interest increase of 364 ADS at $46.5400. Separately, President Maya Martinez-Davis acquired 179.308 ADS at $46.5400, and Brown acquired 2,409.639 ordinary shares at £17.3550 under the Performance Share Plan, subject to a 2-year holding period.

Key Figures

Ordinary-share transaction price: £17.3550 per ordinary share ADS transaction price: $46.5400 per ADS Luke Miels notional-interest increase: 1,413 ordinary shares +5 more

8 metrics

Ordinary-share transaction price £17.3550 per ordinary share Reported ordinary-share transactions on October 12, 2026

ADS transaction price $46.5400 per ADS Reported ADS transactions on October 12, 2026

Luke Miels notional-interest increase 1,413 ordinary shares Deferred Annual Bonus Plan transaction on October 12, 2026

Julie Brown notional-interest increase 1,863 ordinary shares Deferred Annual Bonus Plan transaction on October 12, 2026

Julie Brown acquisition 2,409.639 ordinary shares Performance Share Plan transaction subject to a 2-year holding period

Shobie Ramakrishnan notional-interest increase 364 ADS Dividend reinvestment transaction on October 12, 2026

Maya Martinez-Davis acquisition 179.308 ADS Dividend reinvestment transaction on October 12, 2026

Performance Share Plan holding period 2 years Applies to Julie Brown’s ordinary-share acquisition

Key Terms

notional interest, Deferred Annual Bonus Plan, American Depositary Shares, Performance Share Plan, +1 more

5 terms

notional interest financial

"Increase in notional interest in Ordinary Shares"

Deferred Annual Bonus Plan financial

"Ordinary Shares held in the Company’s Deferred Annual Bonus Plan"

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares (‘ADS’)"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Performance Share Plan financial

"Ordinary Shares held in the Company’s Performance Share Plan"

A performance share plan grants company shares to employees or executives only if the business meets specific targets over a set period, so the reward depends on results rather than being automatic. For investors it matters because it aligns managers’ pay with company performance—like promising a team stock instead of cash if they hit goals—which can influence future share count, shareholder value, and how confidently management pursues growth.

2-year holding period financial

"subject to a 2-year holding period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What price did GSK’s reported dividend-reinvestment transactions use?

Ordinary-share transactions were priced at £17.3550, while ADS transactions were priced at $46.5400. The transactions occurred on October 12, 2026, following dividend payments on October 8, 2026.

What ADS transactions did GSK report?

Chief Digital and Technology Officer Shobie Ramakrishnan had a notional-interest increase of 364 ADS, and President Maya Martinez-Davis acquired 179.308 ADS. Both transactions were priced at $46.5400 on October 12, 2026, following dividends paid on October 8, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/14/2026 - 11:43 AM EDT Accepted by SEC EDGAR 10/14/2026 - 11:42 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the ‘Company’)

Transaction notification

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	756
			£17.3550	379
			£17.3550	278
		d)	Aggregated information Aggregated volume Price	1,413 £17.3550
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	607
			£17.3550	707
			£17.3550	549
		d)	Aggregated information Aggregated volume Price	1,863 £17.3550
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	406
			£17.3550	246
			£17.3550	131
		d)	Aggregated information Aggregated volume Price	783 £17.3550
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares (‘ADS’) ISIN: US37733W2044
b)	Nature of the transaction	Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 8 October 2026 on ADS held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5400	188
			$46.5400	113
			$46.5400	63
		d)	Aggregated information Aggregated volume Price	364 $46.5400
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	481
			£17.3550	219
			£17.3550	194
		d)	Aggregated information Aggregated volume Price	894 £17.3550
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	579
			£17.3550	321
			£17.3550	203
		d)	Aggregated information Aggregated volume Price	1,103 £17.3550
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	324
			£17.3550	195
			£17.3550	141
		d)	Aggregated information Aggregated volume Price	660 £17.3550
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	501
			£17.3550	302
			£17.3550	184
		d)	Aggregated information Aggregated volume Price	987 £17.3550
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	618
			£17.3550	281
			£17.3550	258
		d)	Aggregated information Aggregated volume Price	1,157 £17.3550
e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$46.5400	179.308
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
		e)	Date of the transaction	2026-10-12
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them (‘PCA’)
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’) ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£17.3550	2,409.639
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
		e)	Date of the transaction	2026-10-12
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: October 14, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc